Deepnoid expands state-funded program lineup to two products... “Expanding into AI for brain aneurysms”

[Financial News]  Deepnoid is expanding the scope of its medical artificial intelligence (AI) solutions supplied through a national support program from chest X-rays to cerebrovascular care. Moving beyond supplying a single product, the company is stepping up efforts to broaden its medical AI business portfolio by bringing AI solutions for different imaging modalities and disease areas to public healthcare settings.
Deepnoid said on the 7th that it will supply its brain aneurysm diagnosis support AI solution, ‘DeepNeuro (DEEP),’ to Chungbuk National University Hospital. This is the first time DeepNeuro has been supplied to a regional responsible medical institution.
The supply was made through the Ministry of Health and Welfare’s ‘Support Project for AI-Based Care Systems at Regional Responsible Medical Institutions.’ Chungbuk National University Hospital operates the Chungbuk Regional Cardiovascular and Cerebrovascular Disease Center and a Regional Emergency Medical Center, among others, and is expected to build up examples of AI solution use in treating severe and emergency cerebrovascular diseases.
What is particularly notable is the expansion of Deepnoid’s product lineup supplied through the national support program. Deepnoid previously supplied its generative AI-based solution for generating preliminary chest X-ray reports, ‘M4CXR,’ to three university hospitals through the same program.
With this supply of DeepNeuro, the program’s product lineup has grown to two. The imaging modality has expanded from chest X-rays to brain MRA, while the target area has broadened from lung diseases to cerebrovascular diseases. Whether references from public medical institutions will lead to wider supply to medical institutions will be a key point to watch.
DeepNeuro is a medical device that uses AI to analyze areas suspected of being brain aneurysms in cerebrovascular MRA images and assist medical professionals with diagnosis. Designated an innovative medical technology, it is being used in clinical settings on a non-reimbursed basis.
A medical AI industry official said, “For medical AI, an important factor in market adoption is how many use cases and references can be built up at actual medical institutions, rather than regulatory approval itself.” The official added, “In particular, whether supply to a regional hub hospital can lead to adoption by other medical institutions will be a key point in assessing the business prospects going forward.”
Meanwhile, Deepnoid has recently been expanding beyond individual image-reading solutions into businesses that support workflows in healthcare settings. Last August, it completed the Ministry of Food and Drug Safety’s regulatory approval process for its remote-reading operations platform, ‘AxonFlow.’
Deepnoid CEO Choi Woo-sik emphasized, “The solution supplied to regional responsible medical institutions has expanded from chest X-rays to brain MRA,” adding, “We will continue to broaden the range of diseases addressed by medical AI solutions through national support programs.”


[email protected] Kim Kyung-a Reporter